Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli

• Plasma proteomics seems feasible and useful in CML patients. • Protein patterns demonstrated a shift towards Th1-immunity after TKI treatment. • Angiogenic factors were decreased after TKI treatment. • Some single analytes were identified that could be of interest to study further in CML.